Antios Therapeutics Appoints Achieved Economical Government, Tamra J. Adams, as its initially Main Economical Officer
ATLANTA, Feb. 17, 2021 (Globe NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) these days declared the appointment of seasoned economic government, Tamra J. Adams, as the Company’s main money officer (CFO) productive March 1, 2021. Ms. Adams fills a newly produced government placement at Antios as element of the Company’s rapid enhancement.
“We have not long ago finished a Stage 1b clinical demo of our guide asset, ATI-2173, a potential backbone remedy in a practical healing program for persistent HBV infection, and anticipate presenting proof-of-idea details from the study in mid-2021,” explained Gregory Mayes, chief executive officer of Antios. “We also search ahead to aggressively relocating the application into Phase 2 which will start up coming thirty day period. For that purpose, incorporating a senior financial executive seasoned with rising progress companies, which includes in biopharmaceuticals, to the executive management group is a crucial stage at this time. Tamra and I labored intently alongside one another at Have interaction Therapeutics for 3 a long time and I appear forward to collaborating with her yet again as we go on to fast advance the improvement of ATI-2173 and evolve as a organization.”
Ms. Adams has far more than 25 years of practical experience in accounting and money administration. Ahead of becoming a member of Antios, she started Accounting Concepts, Inc., a company that offered CFO, accounting, and economical products and services to emerging progress companies in the biopharmaceutical and details technological know-how industries, which includes Have interaction Therapeutics, a organization that was bought to UCB in 2020. Right before that, Ms. Adams was a senior economical executive at Silverstorm Systems, Inc., where by she was responsible for financial and human assets features and participated in an acquisition of the enterprise by QLogic. Prior, she was the Controller of Starcite, Inc., an net enterprise, where by she was liable for monetary reporting, company product enhancement and internal command techniques. Ms. Adams commenced her vocation at Ernst & Young, LLP, as a Senior Auditor specializing in entrepreneurial products and services and afterwards at Goldman Sachs as a Senior Accounting Officer. Ms. Adams attained her B.S. in Accounting at Condition University of New York, Albany and is a qualified community accountant in New York.
“I have expended the the vast majority of my vocation running the monetary infrastructure for rising growth firms and doing the job with Antios gives me the opportunity to go on constructing on that work,” stated Ms. Adams. “The organization is on a fast progress trajectory and has the potential to make a sizeable contribution to community wellness. I look forward to supporting make Antios into a leading biopharmaceutical enterprise with the rest of the workforce.”
About ATI-2173

ATI-2173 is a novel, orally administered, liver-focused Lively Web page Polymerase Inhibitor Nucleotide (ASPIN) molecule built to provide the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s lively 5’-triphosphate has special antiviral qualities as a non-aggressive, non-chain terminating HBV polymerase inhibitor that distorts the active internet site of HBV polymerase ensuing in strong HBV antiviral activity and prolonged off-remedy suppression of HBV DNA. ATI-2173 targets the liver, offering high degrees of the exceptional 5’- triphosphate when limiting systemic exposure to the guardian L-nucleoside. ATI-2173 has the opportunity to become an integral portion of a curative combination regimen for long-term hepatitis B.
About Antios Therapeutics Inc.

Antios Therapeutics is a clinical-stage biopharmaceutical enterprise centered on the enhancement of revolutionary therapies to treat and cure viral disorders. Antios is presently creating ATI-2173, aiming to offer serious hepatitis B infected individuals with a healing combination regimen.
CONTACTS
Investors:

Lee Roth

Burns McClellan
[email protected]

+1 (212) 300-8331
Media:

Ryo Imai / Robert Flamm, Ph.D.

Burns McClellan
[email protected] / [email protected]

+1 (212) 300-8315 / +1 (212) 300-8364
